Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Magnesium Sulphate Halves Risk Of Eclampsia And Can Save Lives Of Pregnant Women

31.05.2002


Giving magnesium sulphate injections to pregnant women with pre-eclampsia halves the risk of eclampsia developing and can save their lives. This is the conclusion of a major international clinical trial funded by the Medical Research Council (MRC) and published in this week’s The Lancet.



The three-year £2.5 million study, the ‘Magpie’* Trial, was conducted in 33 countries spanning the UK and much of the developing world where eclampsia is the most common cause of death for pregnant women. The trial involved over 10,000 women.

All of the women were suffering from pre-eclampsia (pregnancy-induced high blood pressure, commonly known as toxaemia) which can lead to eclampsia (convulsions) which threatens both the mother’s and the baby’s lives.


In addition to normal medical care, half the women in the trial were randomly assigned to receive an injection of magnesium sulphate, an anticonvulsant drug. The other half was allocated a placebo treatment.

Women allocated magnesium sulphate had a 58% lower risk of eclampsia than those allocated the placebo. Although the treatment did not affect whether or not the baby died, there was evidence that it can reduce the risk of the mother dying. A quarter of women reported minor side effects but there was no evidence of harmful effects to either the mother or baby.

Dr Lelia Duley, an MRC Senior Clinical Fellow and Obstetric Epidemiologist in the Institute of Health Sciences at the University of Oxford, led the research.

She said: “Eclampsia is a devastating condition that can kill both mother and child. Our trial has shown that giving magnesium sulphate injections halves the risk of developing eclampsia for women who already have pre-eclampsia, and it seems likely it also reduces the risk of maternal death. The treatment could save countless lives across the world if it was introduced routinely for pregnant women with pre-eclampsia. And, importantly, it is a very inexpensive treatment, making it especially suitable for use in low income countries.”

Professor Jim Neilson, Professor of Obstetrics and Gynaecology at the University of Liverpool, was one of the clinicians who worked on the trial. He said: “Anticonvulsant drugs have been given to some women with pre-eclampsia for several years but this is the first time that we’ve shown clear benefits for magnesium sulphate treatment through a major research study. These exciting results should now change routine clinical practice across the UK and the world.”

Claire Giles, a woman who suffered pre-eclampsia during her first pregnancy and who took part in the trial, said: “I was really pleased to be part of such an important trial. I developed swelling at 32 weeks which grew progressively more severe until I was finally diagnosed with pre-eclampsia and admitted to hospital at 38 weeks. My baby was delivered by caesarean section and thankfully we both made a complete recovery. Pre-eclampsia is a frightening condition and I really hope that the results of the trial will benefit women like me.”

One in ten pregnant women world-wide suffers from pre-eclampsia, often in their first pregnancy. Currently the only definitive treatment is to deliver the baby early. Once the baby is born the mother’s blood pressure usually returns to normal although the baby will often require intensive medical care due to being born prematurely.

Women seeking further information about pre-eclampsia and eclampsia can call the Action on Pre-eclampsia (APEC) Helpline on 020 8427 4217 (weekdays 10am - 1pm).

The research was funded mainly by the Medical Research Council with support from the Department for International Development, the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction and the European Commission, DG Research, INCO Programme.

Press Office | alphagalileo

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

NASA's Fermi catches gamma-ray flashes from tropical storms

25.04.2017 | Physics and Astronomy

Researchers invent process to make sustainable rubber, plastics

25.04.2017 | Materials Sciences

Transfecting cells gently – the LZH presents a GNOME prototype at the Labvolution 2017

25.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>